Skip to Contents

“One step to excellence”
Hanmi, your best CDMO partner.


  • Tailored end-to-end services

  • State-of-the-art cGMP
    approved facilities

  • Experts for every step

Hanmi Pharmaceutical provides a comprehensive range of services throughout the entire pharmaceutical life cycle, from the supply of raw materials (chemical API, Peptide, PEG, mRNA cap analog, NTP, Lipid, etc.) through its
affiliate, Hanmi Fine Chemical, to the development and production of chemically synthesized pharmaceuticals and biopharmaceuticals. Partnership with Hanmi Fine Chemical, Paltan Smart Plant, and
Pyeongtaek Bioplant means the highest quality is assured.

Hanmi Pharmaceutical provides the best CDMO service to customers worldwide based on its R&D capabilities and state-of-the-art facilities. Hanmi aims to be the best partner in realizing customer-tailored services through skilled professionals and top-notch facilities. We want to share our experience in
developing and producing products in the fastest and highest quality manner through optimized routes with healthcare companies around the world.



Hanmi Pyeongtaek Bioplant, located in Pyeongtaek, Gyeonggi-do, Korea, manufactures and supplies excellent biopharmaceutical products
worldwide. Through approvals from MFDS and the US FDA, Pyeongtaek Bioplant is supplying commercial biopharmaceutical products to both the US and Korean markets.

Pyeongtaek Bioplant is equipped with state-of-the-art large-scale manufacturing facilities optimized for the commercial production of microbial-based biopharmaceuticals, including bioreactors with a maximum capacity of 12,500 liters. Additionally, the site houses advanced manufacturing facilities for prefilled syringes, capable of producing over 30 million units annually.

  • Development to production of
    raw materials and finished pharmaceutical products, and comprehensive services for the entire process
  • FDA-approved quality systems and manufacturing and management
  • Excellent human resources and state-of-the-art equipment resources, securing flexibility

GMP Testing and Analysis management

  • GMP Raw material testing and management
  • IPC & Release testing
  • Stability testing & Characterization
  • Electronic management systems

Biologics GMP Drug Substance Manufacturing

  • Microbial Fermentation Process
  • Recovery & Purification-Chromatography Process
  • PEGylation and Conjugation Process
  • DNA and mRNA synthesis

Biologics GMP Drug Product Manufacturing

  • Prefilled syringe Aseptic Fill & Finish
  • Automatic Visual Inspection
  • Final packaging of drug (Blistering & Cartoning)

Status of Certification

Status of Certification
NO Date Country Contents
1 Aug. 2007 Republic of Korea / MFDS MFDS Pre-approval of GMP Plant (PIC/S)
2 Nov. 2008 Republic of Korea / MFDS MFDS Pre-approval of BGMP
3 Jan. 2011 UK / SGS Certificate of ISO13485
4 Jun. 2015 Republic of Korea / Korea Foundation of Quality Certificate of ISO14001
5 Dec. 2019 Republic of Korea / Korea Foundation of Quality Certificate of ISO45001
6 May. 2018 USA / FDA Premarket approval application(PMA) for SYNOJOYNT
7 Nov. 2019 Republic of Korea / MFDS MFDS GMP Compliance approval of API&DP
8 Sep. 2022 USA / FDA BLA Approval for Rolvedon
9 May. 2023 Republic of Korea / MFDS Certificate of GMP Compliance of a Biopharmaceuticals Contract Manufacturing Organization

Fine Chemical


Hanmi Fine Chemical is an affiliate of Hanmi Pharmaceutical located in Siheung, Gyeonggi-do, Korea. Fine Chemical is expanding its scope beyond small molecule APIs and Incrementally Modified Drug development by entering the CDMO business.

In addition to cGMP production facilities, API mass production capacity, and
systematic GMP operation, Hanmi Fine Chemical has secured advanced development technologies in mRNA (cap analog, etc.) materials, PEG, and peptides through proprietary R&D based on its accumulated experience in new drug development. ‘Customized service’ is available for each step, from process development and analysis method development to GMP production. Regulatory documents and audits required by health authorities are also fully available.

  • IP secured Hanmi Cap, PEG, peptide, and pre-established manufacturing facility
  • Inspection experiences by major health authorities and numerous customer audit histories (US FDA, EMA, Japan PMDA, Portugal INFARMED, Australia TGA, etc)
  • Partnership histories with various global
    big pharmas (Lilly, Roche, Sanofi, MSD, Janssen, etc)


  • Glass Lining 75m3(8 sets)
  • STS 316L 80m3 (8 sets)
  • Hastelloy C-22 40m3 (5 sets), 1m3, 0.5m3, 0.3 m3
  • Glass Filter Reactor : 2.5L, 10L, 200L
  • Glass Reactor : 100L(2 sets)

Filtration & Drying

  • Nutsche Filter 10.2m3(17 sets)
  • Centrifuge (basket nominal volume 336L)
  • Filter Dryer 15m3(5 sets), Double Cone Vacuum Dryer 3m3, Conical Vacuum Dryer 1.5m3


  • Lyophilizer 20kg, 200kg, 300kg(Ice Capacity)


  • Air Jet mill, Hammer type mill

Status of Certification

Status of Certification
NO Date Country Contents
1 May. 2016 System Korea Certification, Korea Occupational Safety & Health Agency Renewal of the Safety and Health Management System (ISO 45001, KOSHA-MS)
2 Jun. 2016 System Korea Certification The Quality Management System certification (ISO 14001) reauthentication
3 Dec. 2019 System Korea Certification "The Business Continuity Management System certification (ISO 22301) reauthentication"
4 Mar. 2023 Minisry of Employment and Labor PMS(Process Safety Management) S grade



Paltan Plant is Hanmi Pharmaceutical's central production base for chemical drugs located in Paltan, Gyeonggi-do, Korea. Paltan Smart Plant can rapidly produce more than 6 billion tablets of chemical drugs annually.

Based on its state-of-the-art system and advanced production process, Paltan Plant was accredited by GMP certification from the most pharmaceutically advanced countries and is currently exporting chemical-finished drugs worldwide. The whole process is equipped with the latest ICT (Information and Communication Technology) technology and 90% of the manufacturing and production process is automated.

  • Smart Plant with automation of process from receiving raw materials to shipping
  • Manufacturing of high-quality pharmaceutical products using information and communication technology (ICT)
  • Excellent manpower and systems to maintain continuous partnerships with global partners


  • Direct dispensing to IBC(Intermediate Bulk Container)
  • IBC to IBC dispensing system using gravity


  • Closed System
  • Vacuum Transferring System

Storage and Transportation

  • Automation of IBC washing
  • Automatic warehouse for intermediates
  • Unmanned transport device (AGF, Automatic Guided Forklift)

Compression/Capsule Filling

  • Closed System


  • Automatic packaging system (primary packaging → warehousing)

Status of Certification

Status of Certification
NO Date Country Contents
1 Jan. 1986 Republic of Korea / MFDS MFDS Pre-approval of GMP Plant
2 Nov. 2017 Japan / PMDA MFDS Pre-approval of GMP Plant
3 Jun. 2019 Russia / MITRF Certificate of GMP Compliance
4 Jan. 2020 Japan / PMDA Certificate of GMP Compliance


Zoom in on the image